Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Koreaopen access
- Authors
- Shim, Ji-Su; Jin, Juhae; Kim, Sae-Hoon; Lee, Taehoon; Jang, An-Soo; Park, Chan Sun; Jung, Jae-Woo; Kwon, Jae-Woo; Moon, Ji-Yong; Yang, Min-Suk; Lee, Jaechun; Choi, Jeong-Hee; Shin, Yoo Seob; Kim, Hee-Kyoo; Kim, Sujeong; Kim, Joo-Hee; Cho, Sang-Heon; Nam, Young-Hee; Kim, Sang-Hoon; Park, So Young; Hur, Gyu Young; Kim, Sang-Ha; Park, Hye-Kyung; Jin, Hyun Jung; Lee, Jae-Hyun; Park, Jung-Won; Yoon, Ho Joo; Choi, Byoung Whui; Cho, Young-Joo; Kim, Min-Hye; Kim, Tae-Bum
- Issue Date
- Dec-2022
- Publisher
- Lippincott Williams & Wilkins Ltd.
- Keywords
- Tiotropium; Muscarinic antagonists; Asthma; Treatment response; Predictor
- Citation
- World Allergy Organization Journal, v.15, no.12
- Journal Title
- World Allergy Organization Journal
- Volume
- 15
- Number
- 12
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22222
- DOI
- 10.1016/j.waojou.2022.100720
- ISSN
- 1939-4551
- Abstract
- 338489296_20221221170722203 responders; 2) doctor-diagnosed asthma-chronic obstructive pulmonary disease overlap (ACO) [OR = 12.6, 95% CI: 1.8-161.5, P = 0.024], and 3) initial ACT score <20 [OR = 24.1, 95% CI: 5.45- 158.8, P < 0.001] for ACT responders. FEV1 responders also showed a longer exacerbation-free period than those with no FEV1 increase (P = 0.014), yielding a hazard ratio for the first asthma exacerbation of 0.5 (95% CI: 0.3-0.9, P = 0.016). Conclusions: The results of this study suggest that tiotropium add-on for uncontrolled asthma with ICS-LABA would be more effective in patients with positive BDR or ACO. Additionally, an increase in FEV1 following tiotropium may predict a lower risk of asthma exacerbation.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22222)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.